Journal
BIOMARKER RESEARCH
Volume 6, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s40364-018-0146-7
Keywords
Acute myeloid leukemia; Molecular landscape; Targeted therapy
Categories
Funding
- National Natural Science Foundation of China [81670159]
- CAMS Innovation Fund for Medical Sciences [CIFMS 2016-I2M-3-004]
- Peking Union Medical College Youth Fund [2017320022]
Ask authors/readers for more resources
For decades, genetic aberrations including chromosome and molecular abnormalities are important diagnostic and prognostic factors in acute myeloid leukemia (AML). ATRA and imatinib have been successfully used in AML and chronic myelogenous leukemia, which proved that targeted therapy by identifying molecular lesions could improve leukemia outcomes. Recent advances in next generation sequencing have revealed molecular landscape of AML, presenting us with many molecular abnormalities. The individual prognostic information derived from a specific mutation could be modified by other molecular lesions. Therefore, the genomic complexity in AML poses a huge challenge to successful translation into more accurate risk stratification and targeted therapy. Herein, a summary of these mutations and targeted therapies are described. We focus on the prognostic information of recent identified molecular lesions and emerging targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available